An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the delivery schedule.

The Trump administration has canceled an upcoming meeting of the Food and Drug Administration’s vaccine advisory committee, a move that could complicate efforts to produce flu shots in time for the upcoming season.

A March meeting of outside advisers to the US Food and Drug Administration to discuss the composition of flu vaccines for this fall’s flu season has been canceled, a member of the advisory committee told CNN.

Now the Johns Hopkins University surgeon and researcher has been nominated to lead the Food and Drug Administration. The agency — responsible for regulating products ranging from toothpaste to vaccines — is famously understated, issuing carefully worded statements devoid of opinion or scientific speculation.

The U.S. Food and Drug Administration confirmed on Thursday that a meeting of its independent advisory panel to discuss the composition of this year's flu vaccine has been canceled and the regulator would instead make recommendations later.

The Food and Drug Administration unexpectedly canceled an annual meeting of its advisers to update next season's influenza vaccines, raising concerns about the timeline for manufacturing next winter's flu shots.

The Food and Drug Administration (FDA) abruptly canceled a vaccine advisory meeting where members were slated to discuss influenza vaccine strains. The meeting was scheduled for March 13.

The advisory committee meeting is a critical resource for vaccine makers trying to figure out which flu strains to include in their shots for the next flu season.

The FDA's decision to cancel the March meeting raises questions about flu vaccine guidance for manufacturers this year